F2R and non-small cell lung carcinoma: Anticoagulant-dependent thrombin inhibition is thus likely to be especially beneficial in NSCLC patients with thrombin-positive/PAR-1 high tumors and patients without these characteristics should be excluded from future anticoagulant trials (Fig. 1).